PURPOSEThe purpose of the study was to examine the construct validity of the Health Utilities Index Mark 2 (HU12) and Mark 3 (HU13) in patients with osteoarthritis (OA) needing total hip arthroplasty (THA).BACKGROUNDOne hundred and fourteen OA patients (mean age = 69.2; SD = 8.9) who were waiting to see a surgeon for an evaluation for THA completed baseline measures that included the HU12, HU13, SF-36, Harris Hip Scale, WOMAC, MACTAR, State-Trait Anxiety Inventory, and the 6-min walk test.METHODSWe examined 87 a priori hypotheses by correlating (one-tailed zero-order correlations) the single-attribute utility scores for the pain, emotion, mobility, ambulation, self-care, dexterity, vision, hearing, and speech attributes of the HU12 and HU13 and the overall HU12 and HU13 utility scores to specified subscales of the other measures.RESULTSThe zero-order correlations confirmed 75% of our a priori hypotheses suggesting that the constructs within the HU12 and HU13 were, in general, related to similar constructs in other measures as expected.CONCLUSIONSThe evidence suggests that HU12 and HU13 are valid for use in OA and THA studies.

01 Oct 2000·Medical Decision MakingQ3 · MEDICINE

A Comparison of HU12 and HU13 Utility Scores in Alzheimer's Disease

Q3 · MEDICINE

Article

Author: Neumann, Peter J. ; Sandberg, Eileen A. ; Weinstein, Milton C. ; Feeny, David ; Kuntz, Karen M. ; Araki, Sally S.

Purpose. The Health Utilities Index (HUI) is a generic, multiattribute, preference-based health-status classification system. The HUI Mark 3 (HU13) differs from the earlier HUI2 by modifying attributes and allowing more flexibility for capturing high levels of impairment. The authors compared HUI2 and HU13 scores of patients with Alzheimer's disease (AD) and caregivers, and contrasted results of a cost-effectiveness analysis of new drugs for AD using the two systems. Methods. In a cross-sectional study of 679 AD patient/caregiver pairs, stratified by patient's disease stage (questionable/mild/moderate/severe/profound/terminal) and setting (community/assisted living/nursing home), caregivers completed the combined HU12/HU13 questionnaire as proxy respondents for patients and for themselves. Results. Mean (SD) global utility scores for patients were lower on the HU13 (0.22[0.26]) than on the HU12 (0.53 [0.21]). Patient HU13 utility scores ranged from 0.47(0.24) for questionable AD to -0.23 (0.08) for terminal AD, compared with a range of 0.73 (0.15) to 0.14 (0.07) for the HU12. Among the 203 patients in the severe, profound, and terminal stages, 96 (48%) had negative global HU13 utility scores, while none had a negative HU12 score. The utility scores for caregivers were similar on the HUI3 (0.87 [0.14]) and HU12 (0.87 [0.11]). Cost-effectiveness analysis of a new medication to treat AD showed somewhat more favorable results using the HU13. Conclusions. The HU12 and HU13 discriminate well across AD stages. Compared with the HU12, the HUI3 yields lower global utility scores for patients with AD, and more scores for states judged worse than dead. The HUI3 may yield substantially different results from the HU12, particularly for persons who have serious cognitive impairments such as AD. Key words: Health Utility Index; Alzheimer's disease ; utility assessment. (Med Decis Making 2000;20:413-422)

100 Deals associated with HU-012

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hyperlipidemias	Discovery	South Korea	Huons Co., Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

HU-012

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation